( 1) and fragmentation of pharmaceutical policies at the regional level (2) . This has turned into drug prices that are generally below major EU countries, both for retail (3) and hospital (4) markets, important market access delays at national and regional levels (5) , and market penetration that is well below the European level for some diseases (6) . This multilevel and complex environment requires an integrated approach to market access actions by the pharmaceutical companies. Market Access Provider (MAP) is a privately owned consultancy, born in 2010, by winning on SCAN project the FISMER funding from Regione Lombardia for innovative start up projects.
OBJECTIVES
Purpose of the SCAN project is to support the industry in managing value proposition for market access, integrating national and regional issues and different functions in the companies (Pricing and reimbursement, Outcome research, Health economics, Public affairs, and Marketing), usually involved into market access actions.
METHODS
Value-based pricing is the key feature of SCAN. Prices are determined according to added value in terms of efficacy, safety, compliance, compared to the standard of care (SOC) for the relevant indication. Added value measurement is validated by a multi-stakeholder panel of Opinion Leaders from different fields: pharmacologists, pharmacoeconomists, and clinicians. The integrated platform is open to all functions involved in MA (marketing, health economics and outcome research, P&R…) that could contribute, populating the model, with the relevan data. The model should be implemented at least 18-24 months before the expected launch date of the product.
HOW SCAN WORKS
The SCAN software is divided into different chapters (Figure 2 ):
1. Main drugs info: includes the therapeutic scheme of the new drug and the comparators chosen, in order to calculate the number of packs used per year and also the annual cost of the already marketed therapies; 2. Epidemiology: the target population is calculated starting from the whole population and the epidemiological data available (prevalence, incidence, mortality rate, eligible population, expected treatment rate…) (figure 2); 3. Assessment of clinical and pharmacoeconomic studies of the drugs vs the chosen comparators. The analyst needs to choose comparable clinical data in terms of efficacy, safety, compliance endpoints using the Jadad scale.
The core output of this phase is the calculation of the difference between the new drug and its comparator,which are summed up in a comparative table. These data are necessary to estimate the relative value of the new drug vs the comparators. . TREATMENT RATE: TREATMENT RATE:
MARKET ACCESS STRATEGY

PRICING
Her-2 neg.
Her-2 pos.
TR Her-2 neg.
TR Her-2 pos.
Target Her-2 neg.
Target Her-2 pos. 
CASE HISTORY RESULTS
To validate the methodology, the authors have applied SCAN to some drugs recently approved in Europe and Italy. One of them is Lapatinib, that has recently got the price for metastatic breast cancer, vs trastuzumab, bevacizumab and docetaxel. Twelve clinical trials have been found, verified / selected according to Jadad scale, and subsequently considered in the value-based price algorithm. Actually, the simulated price id close to 1,500 € vs the approved by AIFA 1,225 € approved.
CONCLUSIONS
The simulations show that SCAN is a useful tool to get a value-based price which takes into account all aspects of a new drug, compared to SOC. The model could be further developed to include assessment of new indications and new drugs with no available SOC. In addition, even if it has been tailored for the industry, it could be used also by third party payers to understand whether they are actually using a value-based approach.
